Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of ...

Herbal Oasis ("Oasis"), the hemp-derived THC-infused social seltzer redefining how people connect, unwind, and celebrate life, is proud to ...

In this study, we identify ATRX, a chromatin remodeler of the SWI/SNF family, as a new binding protein of the cohesin complex. ATRX directly interacts with the cohesin accessory subunit Pds5B, ...

Long-term outcomes in GIST Trial 13-162: Phase II study of imatinib in combination with binimetinib in untreated patients with advanced gastrointestinal stromal tumor (GIST). This is an ASCO Meeting ...

along with its functional mushroom brand ATRx Labs, announced today that the automatic conversion (the "Conversion") of shares of its 8% Series A Cumulative Convertible Preferred Stock (the "Preferred ...

ATRX SEC Filings Filing Type: Financials Adhera Therapeutics, Inc. (ATRX) - 10-Q - Quarterly Report SEC Filings Mon, Nov. 20, 2023 Adhera Therapeutics, Inc. (ATRX) - 10-Q - Quarterly Report SEC ...

Compare To: ATRX Compare Select to analyze similar companies using key performance metrics; select up to 4 stocks. ATRX Adhera Therapeutics, Inc. 0.0001 0.00% Mkt cap 722 Industry Biotechnology SEELQ ...

SEC Filings provided by EDGAR Online, Inc.